Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing

Research output: Contribution to journalArticlepeer-review

Abstract

As routine testing of clinical isolates for extended-spectrum β-lactamase (ESBL) production (screen plus phenotypic confirmatory testing) is no longer required by the Clinical and Laboratory Standards Institute (CLSI), a number of clinical microbiology laboratories use ceftriaxone MICs as a proxy means of identifying bacteria as potential ESBL producers. Data from 1,386 clinical isolates suggest that a ceftriaxone MIC cutoff of 8 μg/ml is an excellent predictor of ESBL production, with a positive predictive value and negative predictive value approaching 100% and 99.5%, respectively.

Original languageEnglish (US)
Pages (from-to)2228-2230
Number of pages3
JournalJournal of clinical microbiology
Volume52
Issue number6
DOIs
StatePublished - Jun 2014

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing'. Together they form a unique fingerprint.

Cite this